单胺氧化酶B抑制剂早期帕金森病。

文章的细节

引用
复制到剪贴板

麦克劳德广告,Counsell CE,艾维斯N,斯托R

单胺氧化酶B抑制剂早期帕金森病。

科克伦数据库系统启2005 7月20;(3):CD004898。

PubMed ID
16034956 (在PubMed
]
文摘

背景:假设,单胺氧化酶B(缺氧)抑制剂改变疾病进展在帕金森病(PD)。临床试验得出了相互矛盾的结果。目的:评估的证据有效性和安全性的随机对照试验早期PD缺氧抑制剂的长期使用。必威国际app搜索策略:我们搜索以下电子数据库:科克伦中心注册的对照试验(中央)(Cochrane图书馆问题2,2004),MEDLINE(去年搜索2004年8月18日)和EMBASE(去年搜索2004年8月18日)。我们还handsearc必威国际apphed神经学和运动障碍会议论文集,检查参考列表相关的研究和其他研究人员联系。选择标准:我们试图包括所有unconfounded随机对照试验与控制缺氧抑制剂相比,左旋多巴和多巴胺受体激动剂的存在与否,在早期PD患者和治疗和随访持续至少一年。数据收集和分析:包含两个独立评论家选择试验,评估方法学质量和提取数据。少量的额外的原始作者提供的数据。随机模型被用来分析结果,在适当的地方。主要结果:十个试验包括(共有2422名患者),使用司立吉林九,一个使用lazabemide。 The methodological quality was reasonable although concealment of allocation was definitely adequate in only four trials. The mean follow up was for 5.8 years. MAO-B inhibitors were not associated with a significant increase in deaths (odds ratio (OR) 1.15; 95% confidence interval (CI) 0.92 to 1.44). They provided small benefits over control in impairment (weighted mean difference (WMD) for change in motor UPDRS score was 3.81 points less with MAO-B inhibitors; 95% CI 2.27 to 5.36) and disability (WMD for change in UPDRS ADL score was 1.50 less; 95% CI 0.48 to 2.53) at one year which, although statistically significant, were not clinically significant. There was a marked levodopa-sparing effect with MAO-B inhibitors which was associated with a significant reduction in motor fluctuations (OR 0.75; 95% CI 0.59 to 0.94) but not dyskinesia (OR 0.97; 95% CI 0.76 to 1.25). The reduction in motor fluctuations was, however, not robust in sensitivity analyses. Although adverse events were generally mild and infrequent, withdrawals due to side-effects were higher (OR 2.36; 95% CI 1.32 to 4.20) with MAO-B inhibitors. AUTHORS' CONCLUSIONS: MAO-B inhibitors do not appear to delay disease progression but may have a beneficial effect on motor fluctuations. There was no statistically significant effect on deaths although the confidence interval does not exclude a small increase with MAO-B inhibitors. At present we do not feel these drugs can be recommended for routine use in the treatment of early Parkinson's disease but further randomized controlled trials should be carried out to clarify, in particular, their effect on deaths and motor complications.

DrugBank数据引用了这篇文章

药物
药物靶点
药物 目标 类 生物 药理作用 行动
优降宁 胺氧化酶(flavin-containing) B 蛋白质 人类
是的
抑制剂
 细节
司立吉林 胺氧化酶(flavin-containing) B 蛋白质 人类
是的
抑制剂
 细节